CHRS

1.15

4.17% -0.05

Handel nachbörslich: 1.25 0.10 +8.70%

Coherus Oncology Inc (CHRS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt CHRS? Forum Prognose

Schlusskurs vom Vortag:

$1.20

Offen:

$1.2

24-Stunden-Volumen:

1.11M

Relative Volume:

1.12

Marktkapitalisierung:

$177.68M

Einnahmen:

$46.88M

Nettoeinkommen (Verlust:

$-172.66M

KGV:

-0.9229

EPS:

-1.2461

Netto-Cashflow:

$-170.57M

1W Leistung:

-7.26%

1M Leistung:

-17.86%

6M Leistung:

-28.57%

1J Leistung:

+9.52%

1-Tages-Spanne:

$1.13

$1.2001

1-Wochen-Bereich:

$1.13

$1.2599

52-Wochen-Spanne:

$1.03

$2.6158

Coherus Oncology Inc Stock (CHRS) Company Profile

Firmenname

Coherus Oncology Inc

Sektor

Healthcare (1082)

Branche

Biotechnology (606)

Telefon

(650) 649-3530

Adresse

C/O DENNIS M. LANFEAR, REDWOOD CITY, CA

Mitarbeiter

145

Twitter

@coherus_bio

Nächster Verdiensttermin

2026-08-05

Neueste SEC-Einreichungen

CHRS's Discussions on Twitter

Compare CHRS vs VRTX, REGN, ARGX, RVMD, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CHRS Coherus Oncology Inc	1.15	185.40M	46.88M	-172.66M	-170.57M	-1.2461
VRTX Vertex Pharmaceuticals Inc	515.55	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.93	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	987.84	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	212.00	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.51	39.31B	5.76B	514.49M	1.10B	4.4813

Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-23	Eingeleitet	Oppenheimer	Outperform
2025-09-04	Hochstufung	Maxim Group	Hold → Buy
2024-08-16	Herabstufung	UBS	Buy → Neutral
2023-11-17	Eingeleitet	Robert W. Baird	Outperform
2023-11-08	Herabstufung	Maxim Group	Buy → Hold
2023-07-24	Eingeleitet	Citigroup	Buy
2023-05-01	Eingeleitet	Truist	Buy
2023-03-28	Hochstufung	UBS	Neutral → Buy
2022-06-14	Eingeleitet	UBS	Neutral
2022-03-07	Herabstufung	JP Morgan	Overweight → Neutral
2020-07-16	Eingeleitet	BofA Securities	Neutral
2020-04-17	Eingeleitet	SunTrust	Buy
2019-08-13	Eingeleitet	Mizuho	Buy
2019-08-02	Bestätigt	H.C. Wainwright	Buy
2019-08-02	Bestätigt	Maxim Group	Buy
2019-06-11	Eingeleitet	Barclays	Overweight
2019-05-07	Eingeleitet	H.C. Wainwright	Buy
2018-08-28	Eingeleitet	H.C. Wainwright	Buy
2018-03-09	Bestätigt	Maxim Group	Buy
2017-08-08	Bestätigt	JP Morgan	Overweight
2017-06-13	Bestätigt	Maxim Group	Buy
2017-05-05	Eingeleitet	BMO Capital Markets	Outperform
2016-10-19	Eingeleitet	Robert W. Baird	Outperform
2016-09-07	Eingeleitet	Maxim Group	Buy
2016-07-27	Eingeleitet	Citigroup	Buy
2016-01-20	Eingeleitet	Credit Suisse	Outperform

Alle ansehen

Coherus Oncology Inc Aktie (CHRS) Neueste Nachrichten

06:54 AM

Form 8K Coherus BioSciences Inc For: 17 August By Investing.com - Investing.com South Africa

06:54 AM

06:53 AM

CHRS Looks 10.6% Overvalued on GF Value™ - GuruFocus

06:53 AM

06:14 AM

Coherus Oncology Secures $55M Term Loan, Extends Debt Maturity to 2031 - Minichart

06:14 AM

05:55 AM

Coherus Declares Special Dividend of Biosimilar Contingent Value Rights, Payable Oct. 7 to Holders of Record Sept. 30 - marketscreener.com

05:55 AM

05:36 AM

Coherus Oncology Announces Special Dividend Of Biosimilar Contingent Value Rights - TradingView

05:36 AM

05:33 AM

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights - GlobeNewswire

05:33 AM

01:17 AM

Earnings call transcript: Coherus Oncology posts Q2 2026 EPS beat, shares fall - Investing.com Nigeria

Aug 07, 2026

Coherus Oncology Price Target Cut to $10.00/Share From $12.00 by Guggenheim - Moomoo

Aug 07, 2026

Aug 06, 2026

H.C. Wainwright Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $7 - Moomoo

Aug 06, 2026

Coherus Oncology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 06, 2026

Coherus Oncology (CHRS) Drops 7.24% to $1.34, Pressing Key Support at $1.27Value ETF - dars.gov.et

Aug 06, 2026